BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Empagliflozin: trial readouts and FDA decisions
2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Boehringer Ingelheim, EMS, Celltrion. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Celltrion | NCT07093476 Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | T2DM; Diabete Type 2; DM | recruiting | 171 |
| 2026-12-31 est. | P3 | Boehringer Ingelheim | NCT06531824 EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Kidney Disease, Chronic | active not recruiting | 8371 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-08-14 | P2 | Boehringer Ingelheim | NCT06926660 A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease | Chronic Kidney Disease | completed | 492 |
| 2026-07 est. | P3 | EMS | NCT05028140 Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus | Type II Diabetes | recruiting | 480 |
| 2026-07 est. | P3 | EMS | NCT04670666 Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus | Type 2 Diabetes Mellitus | recruiting | 270 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.